Sotatercept Completed Phase 2 Trials for Low to Intermediate-1 MDS / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Anemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01736683Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)